AKT1 and glioblastoma: These data show that glioblastoma ICI responders achieve lymphocytic immune cell infiltration, while glioblastoma ICI non-responders are infiltrated with myeloid cells after treatment and are enriched in MAPK and PI3K-AKT signaling before treatment, both of which are modulated by IL-6.